DOCSLIB.ORG

Genetics and Genomics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

31st International Symposium on ALS/MND Theme 02 – Genetics and Genomics GEN-01: An Interval Look at Early outcomes of strength (ATLIS), bulbar function (quantitative speech analysis and IOPI), and disease Markers of Disease in Familial ALS progression (change in ALSFRS-R total score over time). Isabel Anez-Brunzual1, Austin Lewis, Katherine Burke1, Multiple measures of strength (ATLIS, HHD) and Diane Lucente1, Jennifer Jockel-Balsarotti2, Margaret cognition (NIH examiner, ALS-CBS) will be evaluated in all participants over time. Clapp2, Amber Malcolm2, Taylor Stirrat1, Stephanie Berry1, Tania Gendron3, Mercedes Prudencio3, Kathryn Results to date: Connaghan4, James Chan5, Jordan Green4, Leonard Petrucelli3, James Berry1, Timothy Miller2, Dr Katharine Interval analysis will be shown for 86 participants Nicholson1 enrolled in the DIALS Network. Forty-one of 86 1Massachusetts General Hospital, Boston, United States, participants are positive for an ALS causative mutation 2Washington University, Saint Louis, United States, 3Mayo (33 C9orf72, 5 SOD1, 1 TARDBP, 1 VAPB, and 1 FIG4). Clinic, Jacksonville, United States, 4MGH Institute of Health Peri-conversion data will be shown for the 4 C9orf72 Professions, Boston, United States, 5Biostatistics Center, MGH, carriers (3 ALS, 1 FTD) who have developed symptoms. Boston, United States Longitudinal strength, bulbar, and cognitive outcome data as well as direct biomarker comparison will be Live Poster Session A, December 9, 2020, 5:10 PM - 5:50 shown. DIALS enrollment and follow-up visits are PM ongoing. Background: Discussion: The validation of sensitive biofluid markers of inciting The DIALS Network dataset is composed of a growing disease pathology and clinical outcomes is crucial to number of pre-symptomatic ALS gene carriers, now detecting early disease, and to understanding the onset including several symptom converters. Increased of familial ALS and preparing for successful prevention sample size and longitudinal evaluation will continue to trials in asymptomatic gene carriers. inform key elements of the conversion period critical to the design of prevention trials in familial ALS. Objective: To identify the earliest biological markers of disease in Acknowledgements: pre-symptomatic ALS gene carriers Muscular Dystrophy Association, ALS Association, ALS Finding a Cure, Target ALS and philanthropy. Methods: Participants are enrolled in the Dominant Inherited ALS (DIALS) Network at Massachusetts General Hospital and Washington University. Genetic testing of over 30 ALS causative genes and potential genetic modifiers is performed, and participants return every 6 months for clinical outcomes and biofluid collection (plasma, serum, whole blood, CSF, PBMCs, urine, skin biopsy). Clinical data is collected using NeuroBANK. Interval biofluid marker analysis includes longitudinal assessment of neurofilament light chain, chitinases, and dipeptide repeat proteins in collaboration with the Petrucelli and Gendron Labs at the Mayo Clinic in Jacksonville FL and the Bowser lab at the Barrow Neurological Institute. In symptom converters, these candidate biomarkers are directly compared to clinical 1 31st International Symposium on ALS/MND Theme 02 – Genetics and Genomics GEN-02: Blood Transcriptomics of ALS 2MIU IL-2. They underwent infusions once daily for 5 days every 28 days for a total of 3 months. Blood Patients in the IMODALS Clinical Trial samples were collected at different time points Ms Ilaria Giovannelli1, Mr Marius Mickunas2, Dr Timothy throughout the trial. White blood cells were isolated Tree2, Prof Gilbert Bensimon3, Prof Nigel Leigh5, Dr Paul and RNA extracted. This was then used to generate microarray gene expression data and for validation Heath1, Prof Dame Pamela Shaw1, Prof Janine Kirby1 1Sheffield Institute for Translational Neuroscience, Department through nanoString and qRT-PCR. of Neuroscience, University of Sheffield, Sheffield, United Kingdom, 2Department of Immunobiology, Faculty of Life Findings: Science and Medicine, King's College London, London, United Blood transcriptome of these patients was analysed at Kingdom, 3Department of Biostatistics, Clinical Epidemiology, day 8 (after the first treatment cycle), 64 (after the third Public Health and Innovation in Methodology (BESPIM), Nîmes and last cycle) and 85 (during follow-up) and changes University Hospital, Nimes, France, 4Department of over the treatment course and under different Pharmacology, AP-HO Sorbonne University, Pitié-Salpêtrière administration regimens were evaluated. Gene 5 Hospital, Paris, France, The Trafford Centre for Biomedical expression analysis together with pathway analysis Research, Brighton and Sussex Medical School, Falmer, revealed a prompt immune-regulatory effect of ld-IL-2 Brighton , United Kigdom after the first treatment cycle with evidence of Live Poster Session A, December 9, 2020, 5:10 PM - 5:50 downregulation of pro-inflammatory processes. This PM early response seemed to diminish during the course of the trial but a robust activation of Treg was only visible Background: after the last treatment cycle. In fact, a time-dependent A spreading inflammatory condition within the CNS, and dose-dependent induction of Treg markers was involving both resident and peripheral immune cells, is registered at day 64 suggesting a cumulative effect of characteristic of amyotrophic lateral sclerosis (ALS). ld-IL-2 on these cells. However, inter-individual Regulatory T cells (Treg) are immune regulators which dissimilarities were identified and patients were suppress the establishment of excessive inflammatory classified into low, mild and high responders. Significant conditions and autoimmune disorders. These cells are transcriptional differences were reported amongst dramatically and progressively reduced in ALS patients these groups in their baseline expression of an and this correlates with the rate of disease progression. immunological transcript cluster. In particular, a more Moreover, evidence shows their functional impairment inflammatory-prone phenotype was documented in ALS individuals. Low-dose interleukin-2 (ld-IL-2) has amongst low responders at recruitment. Finally, a been proposed as a therapeutic strategy to promote predictive biomarker analysis was then carried out to Treg expansion and a physiological restoration of the identify small sets of transcripts able to forecast an ALS immune balance. This cytokine is crucial for Treg individual's reaction to ld-IL-2. We discovered that the differentiation, activation and functions and thus it is expression of two genes was able to predict Treg count hypothesized to boost Treg-mediated immune- at the end of the trial, given their gene expression at suppression and dampen neuroinflammation in these time of recruitment. patients. Aim: To evaluate the effect of ld-IL-2 on the blood transcriptome of ALS patients included in the IMODALS clinical trial (NCT02059759). Methods: Thirty-six ALS patients were recruited and randomly assigned to three treatment arms: placebo, 1MIU or 2 31st International Symposium on ALS/MND Theme 02 – Genetics and Genomics GEN-03: Dissecting the sex-dependent significantly enriched in genes highly expressed in the brain, consistent with the known aetiology of ALS. genetic architecture of amyotrophic Finally, per-chromosome heritability estimates (GREML) lateral sclerosis showed a linear relationship with chromosome length in females (r2=0.27;p=0.0074), but not males Mr Ross Byrne1, Dr Wouter van Rheenen2, Prof Jan (r2=0.009,p=0.286) suggesting ALS is more polygenic in Veldink2, Dr Russell L McLaughlin1 females. This observation was supported by analysis 1Smurfit Institute of Genetics ,Trinity College Dublin, Dublin, using Heritability Estimation from Summary Statistics 2 Ireland, Department of Neurology and Neurosurgery, (HESS), which showed a greater proportion of the University Medical Center Utrecht, Utrecht, The Netherlands genome contributed to ALS heritability in females. Our Live Poster Session A, December 9, 2020, 5:10 PM - 5:50 findings suggest the genetic component of ALS differs PM between sexes. Sex affects the prevalance[1], site of onset[1], and even References: heritability[2] of ALS, with evidence that both male[3] 1. McCombe PA, Henderson RD. Gend Med. and female[4,5] sex hormones modify disease risk. 2010;7: 557–570. However, to date the extent to which sex affects the 2. Ryan M et al. JAMA Neurol. 2019. genetic architecture of ALS has not been addressed. doi:10.1001/jamaneurol.2019.2044 We calculated the genetic overlap between sexes in ALS 3. Leigh PN et al. J Neurol Neurosurg Psychiatry pedigrees using published sex-stratified heritability 2011;82(6):635-7 estimates[2], showing an imperfect genetic correlation 4. de Jong S et al. J Neurol. 2013;260: 507–512. between males and females of just 62.8% (48%-73.2%). 5. Rooney JPK et al. Neurology. 2017;89: 1283– To answer whether this can be explained by common 1290. variants, we reanalysed 36,052 samples from a 6. van Rheenen W et al. Nat Genet. 2016;48: published ALS GWAS[6], accounting for gene-by-sex 1043–1048 interactions. Firstly, we ran GREML analysis of ALS heritability fitting sex as an interaction term and observed significant evidence of a gene-by-sex interaction (likelihood-ratio test: p=0.0087) accounting for 1/3rd of the total SNP heritability. Next we ran GWAS using linear mixed model on stratified male- specific (N=18,732) and female-specific (N=17,322) subsets of the data to further dissect sex effects. We estimated heritability using
Recommended publications
  • Genome-Wide Analyses Identify KIF5A As a Novel ALS Gene

    Genome-Wide Analyses Identify KIF5A As a Novel ALS Gene

    This is a repository copy of Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/129590/ Version: Accepted Version Article: Nicolas, A, Kenna, KP, Renton, AE et al. (210 more authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 97 (6). 1268-1283.e6. https://doi.org/10.1016/j.neuron.2018.02.027 Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Genome-wide Analyses Identify KIF5A as a Novel ALS Gene Aude Nicolas1,2, Kevin P. Kenna2,3, Alan E. Renton2,4,5, Nicola Ticozzi2,6,7, Faraz Faghri2,8,9, Ruth Chia1,2, Janice A. Dominov10, Brendan J. Kenna3, Mike A. Nalls8,11, Pamela Keagle3, Alberto M. Rivera1, Wouter van Rheenen12, Natalie A. Murphy1, Joke J.F.A. van Vugt13, Joshua T. Geiger14, Rick A. Van der Spek13, Hannah A. Pliner1, Shankaracharya3, Bradley N.
  • Analysis of Shared Common Genetic Risk Between Amyotrophic Lateral Sclerosis and Epilepsy

    Analysis of Shared Common Genetic Risk Between Amyotrophic Lateral Sclerosis and Epilepsy

    Neurobiology of Aging xxx (2020) 1.e1e1.e5 Contents lists available at ScienceDirect Neurobiology of Aging journal homepage: www.elsevier.com/locate/neuaging Negative results Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy Dick Schijvena,b,c, Remi Stevelinkd, Mark McCormackd,e, Wouter van Rheenena, Jurjen J. Luykxb, Bobby P.C. Koelemand, Jan H. Veldinka,*, on behalf of the Project MinE ALS GWAS Consortium International League Against Epilepsy Consortium on Complex Epilepsies a Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands b Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands c Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands d Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands e Department of Molecular and Cellular Therapeutics, The Royal College of Surgeons in Ireland, Dublin, Ireland article info abstract Article history: Because hyper-excitability has been shown to be a shared pathophysiological mechanism, we used the Received 23 September 2019 latest and largest genome-wide studies in amyotrophic lateral sclerosis (n ¼ 36,052) and epilepsy (n ¼ Received in revised form 31 January 2020 38,349) to determine genetic overlap between these conditions. First, we showed no significant ge- Accepted 10 April 2020 netic correlation, also when binned on minor allele frequency. Second, we confirmed the absence of polygenic overlap using genomic risk score analysis. Finally, we did not identify pleiotropic variants in meta-analyses of the 2 diseases.
  • Value of Systematic Genetic Screening of Patients with Amyotrophic Lateral

    Value of Systematic Genetic Screening of Patients with Amyotrophic Lateral

    Neurodegeneration J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-325014 on 14 February 2021. Downloaded from Original research Value of systematic genetic screening of patients with amyotrophic lateral sclerosis Stephanie R Shepheard ,1 Matthew D Parker,1 Johnathan Cooper- Knock ,1 Nick S Verber,1 Lee Tuddenham,1 Paul Heath,1 Nick Beauchamp,2 Elsie Place,2 Elizabeth S A Sollars,2 Martin R Turner ,3 Andrea Malaspina,4 Pietro Fratta,5,6 Channa Hewamadduma,7 Thomas M Jenkins ,1 Christopher J McDermott ,1 Dennis Wang,8 Janine Kirby,1 Pamela J Shaw ,1,7 on behalf of the Project MINE Consortium ► Additional material is ABSTRACT mild cognitive impairment, with approximately published online only. To view, Objective The clinical utility of routine genetic 5% progressing to clinically recognised fronto- please visit the journal online 1 (http:// dx. doi. org/ 10. 1136/ sequencing in amyotrophic lateral sclerosis (ALS) is temporal dementia (FTD). While the majority of jnnp- 2020- 325014). uncertain. Our aim was to determine whether routine ALS cases are considered sporadic (sALS), 5%–10% targeted sequencing of 44 ALS- relevant genes would have been shown to be familial, usually with auto- For numbered affiliations see have a significant impact on disease subclassification somal dominant inheritance, and the genetic cause end of article. and clinical care. of approximately 60%–70% of familial ALS (fALS) 2 Methods We performed targeted sequencing of a 44- cases has now been identified. The most common Correspondence to Professor Pamela J Shaw, gene panel in a prospective case series of 100 patients genetic cause of ALS is due to expansion of a Sheffield Institute for with ALS recruited consecutively from the Sheffield GGGGCC (G4C2) hexanucleotide repeat in the Translational Neuroscience, The Motor Neuron Disorders Clinic, UK.
  • Evidence for Polygenic and Oligogenic Basis of Australian Sporadic

    Evidence for Polygenic and Oligogenic Basis of Australian Sporadic

    Neurogenetics J Med Genet: first published as 10.1136/jmedgenet-2020-106866 on 14 May 2020. Downloaded from Original research Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis Emily P McCann ,1 Lyndal Henden ,1 Jennifer A Fifita ,1 Katharine Y Zhang,1 Natalie Grima ,1 Denis C Bauer ,2 Sandrine Chan Moi Fat ,1 Natalie A Twine ,1,2 Roger Pamphlett ,3,4,5 Matthew C Kiernan,4,6 Dominic B Rowe ,1,7 Kelly L Williams ,1 Ian P Blair 1 ► Additional material is ABSTRact present with limb onset and 25% with bulbar onset, published online only. To view, Background Amyotrophic lateral sclerosis (ALS) is a while rare cases show truncal onset.3 The median please visit the journal online fatal neurodegenerative disease with phenotypic and disease course is 3 years,2 however survival can be (http:// dx. doi. org/ 10. 1136/ 2 4 jmedgenet- 2020- 106866). genetic heterogeneity. Approximately 10% of cases are as short as 12 months and may exceed 20 years. familial, while remaining cases are classified as sporadic. Around 10%–15% of ALS cases are diagnosed with For numbered affiliations see To date, >30 genes and several hundred genetic variants comorbid frontotemporal dementia (FTD), with up end of article. have been implicated in ALS. to 50% developing some cognitive impairment.5 Methods Seven hundred and fifty- seven sporadic Approximately 10% of ALS cases have a family Correspondence to Dr Ian P Blair, Biomedical ALS cases were recruited from Australian neurology history of disease (familial ALS (FALS)) and two- Sciences, Macquarie University clinics.
  • 2018 National ALS Registry Annual Meeting Executive Summary

    2018 National ALS Registry Annual Meeting Executive Summary

    ATSDR’s Annual ALS Surveillance Meeting Summary Report August 1-2, 2017 2018 National ALS Registry Annual Meeting Executive Summary The cause(s) of ALS (Amyotrophic Lateral Sclerosis) remain unknown for 90-95 percent of those diagnosed with the disease and there is still no cure. The Agency for Toxic Substances and Disease Registry (ATSDR) established the National ALS Registry to determine how many people in the US are living with ALS, to describe the demographics of ALS patients, and most importantly to examine the risk factors for ALS. Although the Registry’s primary purpose is to capture cases of ALS, the Registry does a lot more than just count cases. The Registry is also: Funding ALS research, Collecting specimens from Registry enrollees through the National ALS Biorepository, Connecting patients with researchers recruiting for ALS clinical trials or epidemiological studies, Obtaining etiologic data from Registry enrollees through 17 different online risk factor modules such as occupational history, military history, residential history, history of traumatic brain injury (TBI), Providing data and biospecimens to scientists to further ALS research. The National ALS Registry Annual Meeting was held in Atlanta on August 7-8, 2018. There were 51 attendees, including persons living with ALS, neurologists, researchers, representatives of national ALS organizations, representatives of pharmaceutical companies, Registry staff, and other ALS experts. Background, Methodology, and State of the Registry Because ALS is a non-notifiable condition, CDC does not receive reports from states of the occurrence of ALS, as it does for most communicable diseases. The novel methodology developed by ATSDR for identifying newly diagnosed ALS cases uses data from national administrative databases (i.e., Medicare and the Veterans Administration) in addition to the information entered into the online Registry web portal by persons living with ALS.
  • Group Statement

    Group Statement

    May 25, 2021 ALS Organizations Double Down on Their Support for Reintroduced Legislation That Will Accelerate Research and Encourage Access to Critical Investigational Therapies for Those Living with ALS. Today, leaders in the House of Representatives and Senate reintroduced the Accelerating Access to Critical Therapies for ALS Act. The ALS Association, I AM ALS, and the Muscular Dystrophy Association (MDA) endorse the revised legislation with this statement: “The Accelerating Access to Critical Therapies (ACT) for ALS Act builds new pathways to fund early access to ALS investigational therapies, accelerates ALS and rare neurodegenerative disease therapeutic development through a public-private partnership, and increases research on, and development of, interventions for rare neurodegenerative diseases through a new Food and Drug Administration (FDA) research grants program. The ALS Association, I AM ALS, and the Muscular Dystrophy Association endorse this legislation that is a paradigm shift in how therapeutic development, access to treatments, and research has been approached in a fatal, fast- progressing disease like ALS. The ACT for ALS will authorize $100 million a year over a five-year period to: (1) create a new grant program that funds access to investigational ALS treatments currently in development from small biotechnology companies for those patients who cannot participate in clinical trials, while concurrently supporting a research objective on how these investigational treatments impact the disease; (2) establish a Health
  • Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry

    Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry

    Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry August 2017 Contents I. INTRODUCTION ................................................................................................................ 1 II. BACKGROUND ................................................................................................................... 2 III. BENEFIT RISK...................................................................................................................... 5 A. General comments .................................................................................................................. 5 B. Evidence of patient and caregiver preferences ....................................................................... 5 C. Implications of patient risk/benefit preferences in ALS ......................................................... 7 1. Alternative endpoints........................................................................................................... 7 2. Placebo control arm ............................................................................................................. 8 3. Threshold for statistical significance ................................................................................... 9 4. Method of delivery ............................................................................................................ 10 5. Role of expanded access and accelerated approval ........................................................... 11 6. Patient protection and need for informed
  • A Er the Wildly Successful Ice Bucket Challenge

    A Er the Wildly Successful Ice Bucket Challenge

    RESEARCH FEBRUARY/MARCH 2015 BY GINA SHAW Azer the Wildly Successful Ice Bucket Challenge ~e Ice Bucket Challenge raised big bucks on social media. Now, the ALS Association tells us where that cold, hard cash is going. As snowstorms and icy winds batter much of the country, it's hard to imagine willingly pouring a bucket of ice water over your head for any reason. But last August—when temperatures were much more forgiving—that's exactly what about 3 million people did. In an astonishing example of the power of social media, a July 31 dare from former Boston College baseball player Pete Frates, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2012, quickly went viral. The dare? Dump ice water on your head within 24 hours of being challenged or donate $100 (or whatever amount you could afford) to the ALS Association or another organization supporting ALS research. Pretty soon, the Ice Bucket Challenge meant dumping ice on your head and donating money, and everyone from your neighbor's preschooler to Bill Gates (with a custom-built ice douser), Oprah Winfrey, Jon Bon Jovi, and entire casts of Broadway shows were doing it—and posting their videos online. Even 86-year-old Ethel Kennedy took the challenge. (President Obama donated but declined the ice; actor Patrick Stewart posted a video of himself writing a check.) In La Jolla, CA, prominent ALS researcher Don Cleveland, PhD, who pioneered a novel therapy that turns off the defective genes that contribute to neurodegenerative diseases, watched the online commotion with skepticism.
  • Genetic Analysis of ALS Cases in the Isolated Island Population of Malta

    Genetic Analysis of ALS Cases in the Isolated Island Population of Malta

    European Journal of Human Genetics (2021) 29:604–614 https://doi.org/10.1038/s41431-020-00767-9 ARTICLE Genetic analysis of ALS cases in the isolated island population of Malta 1,2 1,2 1 1 3 Rebecca Borg ● Maia Farrugia Wismayer ● Karl Bonavia ● Andrew Farrugia Wismayer ● Malcolm Vella ● 4 4 4 1,2 4 Joke J. F. A. van Vugt ● Brendan J. Kenna ● Kevin P. Kenna ● Neville Vassallo ● Jan H. Veldink ● Ruben J. Cauchi 1,2 Received: 6 May 2020 / Revised: 16 October 2020 / Accepted: 23 October 2020 / Published online: 7 January 2021 © The Author(s) 2020. This article is published with open access Abstract Genetic isolates are compelling tools for mapping genes of inherited disorders. The archipelago of Malta, a sovereign microstate in the south of Europe is home to a geographically and culturally isolated population. Here, we investigate the epidemiology and genetic profile of Maltese patients with amyotrophic lateral sclerosis (ALS), identified throughout a 2-year window. Cases were largely male (66.7%) with a predominant spinal onset of symptoms (70.8%). Disease onset occurred around mid-age (median age: 64 years, men; 59.5 years, female); 12.5% had familial ALS (fALS). Annual incidence rate – 1234567890();,: 1234567890();,: was 2.48 (95% CI 1.59 3.68) per 100,000 person-years. Male-to-female incidence ratio was 1.93:1. Prevalence was 3.44 (95% CI 2.01–5.52) cases per 100,000 inhabitants on 31st December 2018. Whole-genome sequencing allowed us to determine rare DNA variants that change the protein-coding sequence of ALS-associated genes.
  • Genetic Correlation Between Amyotrophic Lateral Sclerosis and Schizophrenia

    Genetic Correlation Between Amyotrophic Lateral Sclerosis and Schizophrenia

    ARTICLE Received 6 Jul 2016 | Accepted 3 Feb 2017 | Published 21 Mar 2017 DOI: 10.1038/ncomms14774 OPEN Genetic correlation between amyotrophic lateral sclerosis and schizophrenia Russell L. McLaughlin1,2,*, Dick Schijven3,4,*, Wouter van Rheenen3, Kristel R. van Eijk3, Margaret O’Brien1, Project MinE GWAS Consortiumw, Schizophrenia Working Group of the Psychiatric Genomics Consortiumz, Rene´ S. Kahn4, Roel A. Ophoff4,5,6, An Goris7, Daniel G. Bradley2, Ammar Al-Chalabi8, Leonard H. van den Berg3, Jurjen J. Luykx3,4,9,**, Orla Hardiman2,** & Jan H. Veldink3,** We have previously shown higher-than-expected rates of schizophrenia in relatives of patients with amyotrophic lateral sclerosis (ALS), suggesting an aetiological relationship between the diseases. Here, we investigate the genetic relationship between ALS and schizophrenia using genome-wide association study data from over 100,000 unique individuals. Using linkage disequilibrium score regression, we estimate the genetic correlation between ALS and schizophrenia to be 14.3% (7.05–21.6; P ¼ 1 Â 10 À 4) with schizophrenia polygenic risk scores explaining up to 0.12% of the variance in ALS (P ¼ 8.4 Â 10 À 7). A modest increase in comorbidity of ALS and schizophrenia is expected given these findings (odds ratio 1.08–1.26) but this would require very large studies to observe epidemiologically. We identify five potential novel ALS-associated loci using conditional false discovery rate analysis. It is likely that shared neurobiological mechanisms between these two disorders will engender novel hypotheses in future preclinical and clinical studies. 1 Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin DO2 DK07, Republic of Ireland.
  • Study Design and Pilot Analyses of a Large-Scale Whole Genome Sequencing Study in Amyotrophic Lateral Sclerosis

    Study Design and Pilot Analyses of a Large-Scale Whole Genome Sequencing Study in Amyotrophic Lateral Sclerosis

    bioRxiv preprint doi: https://doi.org/10.1101/152553; this version posted June 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Project MinE: study design and pilot analyses of a large-scale whole genome sequencing study in amyotrophic lateral sclerosis Project MinE ALS Sequencing Consortium* *A full list of consortium members appears at the end of this manuscript Correspondence Jan H. Veldink Department of Neurology, Brain Center Rudolf Magnus University Medical Center Utrecht Utrecht, The Netherlands [email protected] bioRxiv preprint doi: https://doi.org/10.1101/152553; this version posted June 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Abstract The most recent genome-wide association study in amyotrophic lateral sclerosis (ALS) demonstrates a disproportionate contribution from low-frequency variants to genetic susceptibility of disease. We have therefore begun Project MinE, an international collaboration that seeks to analyse whole-genome sequence data of at least 15,000 ALS patients and 7,500 controls. Here, we report on the design of Project MinE and pilot analyses of newly whole-genome sequenced 1,264 ALS patients and 611 controls drawn from the Netherlands. As has become characteristic of sequencing studies, we find an abundance of rare genetic variation (minor allele frequency < 0.1%), the vast majority of which is absent in public data sets.

  • The Ice Bucket Challenge Chatter the Campaign Went Viral Who's Talking

    TREATO: AFTER THE ALS ICE BUCKET CHALLENGE, WHAT IS THE HEALTH CONSUMER SAYING? Last summer’s ALS Ice Bucket Challenge was one of the most successful social media campaigns of all-time. Millions dumped a bucket of ice water on their head to promote awareness of the disease amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's Disease) and encourage donations to the ALS Association. Round Rock High School Dragon Band - photo by Henry Huey The campaign went viral More than 1billion 2.4 views million + videos posted to Watch Bill Gates ice #donate bucket challenge! $220 #ALS @alsassociation million raised Promoting awareness & AUGUST So what did the health consumer really think of such a grand campaign? With August creeping closer, will we see the same social virality that 1 2015 consumed YouTube and Facebook a year earlier? Online activity Discussions about ALS over time % Posts Monthly Although campaign sustainability was short, conversations still remain stead- ily higher than a year ago. 4/1/2014 7/1/2014 10/1/2014 1/1/2015 4/1/2015 ALS discussions grew by close to 6x the normal activity from July through August, a reflection the effectiveness of the ALS campaign Discussions about ice bucket challenge and ALS over time 35% Almost 30% of the ALS 30% discussions last August were 25% 20% about the ice bucket challenge. 15% The conversations then dropped 10% but we are beginning to see a 5% rise again this June. 0% Who's talking? 44% of all patients discussing ALS The percentage of caregivers are within the 30-49 age group, in talking about ALS is considerably contrast to a disease that is most higher than with other conditions prominent in the 50+ age group.